CR20210222A - Métodos de tratamiento de enfermedad renal crónica con dapagliflozina - Google Patents

Métodos de tratamiento de enfermedad renal crónica con dapagliflozina

Info

Publication number
CR20210222A
CR20210222A CR20210222A CR20210222A CR20210222A CR 20210222 A CR20210222 A CR 20210222A CR 20210222 A CR20210222 A CR 20210222A CR 20210222 A CR20210222 A CR 20210222A CR 20210222 A CR20210222 A CR 20210222A
Authority
CR
Costa Rica
Prior art keywords
dapagliflozin
methods
kidney disease
chronic kidney
treatment
Prior art date
Application number
CR20210222A
Other languages
English (en)
Inventor
Anna Maria Langkilde
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority claimed from PCT/EP2021/058727 external-priority patent/WO2022022865A1/en
Publication of CR20210222A publication Critical patent/CR20210222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a métodos de tratamiento de pacientes con enfermedad renal crónica (ERC), con y sin diabetes tipo 2, con un inhibidor de SGLT2, tal como dapagliflozina.
CR20210222A 2020-07-27 2021-04-01 Métodos de tratamiento de enfermedad renal crónica con dapagliflozina CR20210222A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063057139P 2020-07-27 2020-07-27
US202063070869P 2020-08-27 2020-08-27
US202063082524P 2020-09-24 2020-09-24
US202063093961P 2020-10-20 2020-10-20
US202063119711P 2020-12-01 2020-12-01
US202163152445P 2021-02-23 2021-02-23
US202163161629P 2021-03-16 2021-03-16
PCT/EP2021/058727 WO2022022865A1 (en) 2020-07-27 2021-04-01 Methods of treating chronic kidney disease with dapagliflozin

Publications (1)

Publication Number Publication Date
CR20210222A true CR20210222A (es) 2022-08-29

Family

ID=79551924

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210222A CR20210222A (es) 2020-07-27 2021-04-01 Métodos de tratamiento de enfermedad renal crónica con dapagliflozina

Country Status (13)

Country Link
EP (1) EP4188389A1 (es)
JP (1) JP2023536009A (es)
KR (2) KR20220097854A (es)
CN (3) CN116392472A (es)
AU (2) AU2021202643B2 (es)
BR (1) BR112021008094A2 (es)
CA (1) CA3116533A1 (es)
CR (1) CR20210222A (es)
DO (1) DOP2021000083A (es)
IL (2) IL311682A (es)
JO (1) JOP20210087A1 (es)
MX (1) MX2021005191A (es)
PE (1) PE20231306A1 (es)

Also Published As

Publication number Publication date
IL282665A (en) 2021-12-01
KR20230149329A (ko) 2023-10-26
AU2021202643A1 (en) 2022-02-10
BR112021008094A2 (pt) 2022-02-22
CN116392472A (zh) 2023-07-07
CN114209689B (zh) 2023-02-17
KR20220097854A (ko) 2022-07-08
CN114209689A (zh) 2022-03-22
CN114630682A (zh) 2022-06-14
MX2021005191A (es) 2022-04-18
DOP2021000083A (es) 2022-04-18
AU2023202490A1 (en) 2023-05-11
EP4188389A1 (en) 2023-06-07
JP2023536009A (ja) 2023-08-23
PE20231306A1 (es) 2023-08-24
JOP20210087A1 (ar) 2023-01-30
AU2021202643B2 (en) 2023-02-02
CA3116533A1 (en) 2022-01-27
IL311682A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1116160T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
CL2023001351A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil.
AR065589A1 (es) Prediccion de respuesta a un inhibidor her
PH12018502593A1 (en) Combinations of linagliptin and metformin
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
CR11486A (es) Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
MX2021000295A (es) Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon.
RS53128B (en) Extending the time of disease progression or survival in patients with ovarian cancers using PERTUZUMAB
MX355482B (es) Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
UY39156A (es) Métodos de tratamiento de enfermedad renal crónica con dapagliflozina
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
BR112022004861A2 (pt) Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
DOP2021000083A (es) Métodos de tratamiento de enfermedad renal crónica con dapagliflozina
AR121738A1 (es) Métodos de tratamiento de enfermedad renal crónica con dapagliflozina
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
AR073585A1 (es) Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo